Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient selection [4]. - The company reported disappointing financial results for Q1 2025, revising its full-year 2025 revenue guidance due to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025 [6].

Company Overview - Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for metastatic melanoma and other solid tumor cancers [2] - The company's primary product, Amtagvi, is a tumor-derived autologous T-cell immunotherapy approved by the FDA on February 16, 2024, and launched commercially on February 20, 2024 [2] Class Action Lawsuit - A securities class action lawsuit has been filed against Iovance and certain current and former officers in the U.S. District Court for the Northern District of California, alleging violations of the Securities Exchange Act of 1934 [1] - The lawsuit claims that during the class period from May 9, 2024, to May 8, 2025, the defendants made false or misleading statements regarding the company's operations and prospects, particularly concerning the performance of new Authorized Treatment Centers (ATCs) [3] Financial Performance - On May 8, 2025, Iovance reported a significant decline in quarterly total product revenue, which was $49.3 million, down from $73.7 million in the previous quarter [4] - The company revised its full-year 2025 revenue guidance from a range of $450 million to $475 million down to $250 million to $300 million, citing challenges with ATC growth trajectories and treatment timelines [4] - Following the release of these financial results, Iovance's share price dropped by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, with unusually high trading volume [4]

LOS ANGELES, May 23, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CLICK HERE BEFORE JULY 14, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to allegations of false or misleading statements regarding the company's growth potential and operational capabilities [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $100,000 in Iovance between August 8, 2024, and May 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Iovance and its executives violated federal securities laws by failing to disclose the true state of the company's growth potential and operational readiness [5]. Group 2: Financial Performance and Stock Impact - On July 25, 2024, Iovance announced its second-quarter financial results for fiscal 2024 and reduced its revenue guidance for the full year, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of patient treatments [6]. - Following the announcement, Iovance's stock price fell dramatically from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [6].

LOS ANGELES, May 23, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period") ...

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

Core Insights - Iovance Biotherapeutics announced five-year results from the Phase 2 C-144-01 clinical trial for Amtagvi, demonstrating a five-year overall survival rate of 20% in patients with advanced melanoma previously treated with immune checkpoint inhibitors [1][2][3] Clinical Trial Results - The C-144-01 trial involved 153 patients with advanced melanoma, showing a median overall survival (OS) of 13.9 months and an objective response rate of 31.4%, with complete responses in 5.9% and partial responses in 25.5% of patients [3][7] - Among responders, the median duration of response was 36.5 months, with 31.3% of responders maintaining ongoing responses at the five-year assessment [3][5] Safety Profile - Adverse events were consistent with known safety profiles of nonmyeloablative lymphodepletion and interleukin-2 administration, with a rapid decrease in incidence within the first two weeks post-infusion and no new or late-onset treatment-related adverse events reported [4][5] Regulatory Approval - The U.S. FDA granted accelerated approval to Amtagvi in February 2024 for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, marking it as the first one-time T cell therapy for solid tumors [7][11] Future Developments - Iovance is conducting the TILVANCE-301 Phase 3 trial to confirm the clinical benefit of Amtagvi in frontline advanced melanoma [7][10]

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit for allegedly misleading investors about its growth potential and ability to meet demand for its cancer treatments [1][2]. Group 1: Lawsuit Details - The lawsuit, Farberov v. Iovance Biotherapeutics, Inc., claims that the company made overwhelmingly positive statements while concealing material adverse facts regarding its operational readiness [2][5]. - The class period for the lawsuit is from May 9, 2024, to May 8, 2025, with a lead plaintiff deadline set for July 14, 2025 [2]. Group 2: Stock Performance - On May 9, 2025, Iovance's stock price dropped approximately 44.8%, falling from $3.17 to $1.75, following the announcement of disappointing financial results and a downward revision of revenue guidance [3]. Group 3: Financial Performance - In its July 2024 announcement, Iovance attributed the lower revenue guidance to a month-long reduction in manufacturing capacity due to maintenance, lower-than-expected sales of Proleukin, and a variable pace in the treatment of patients with newer therapies [4]. Group 4: Investor Claims - Investors argue that the disclosures revealed previously concealed issues that negatively impacted the company's growth prospects, contradicting earlier positive statements about its operational readiness [5].

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/iovance-biotherapeutics ...

NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=149542&from=4CLASS PERI ...